

# PEARLS



Practical Evidence About Real Life Situations

Insufficient evidence for baclofen in alcohol withdrawal

### **Clinical question**

How effective is baclofen for patients with alcohol withdrawal syndrome (AWS)?

## **Bottom line**

Oral baclofen 30mg/day (divided into 3 doses) for 10 consecutive days is safe and well-tolerated in the treatment of AWS. Baclofen significantly decreased the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) score, and sweating, tremors, anxiety and agitation score. Although there were significantly higher scores for baclofen compared with diazepam on days 2 and 3, on subsequent days the efficacy of baclofen and diazepam were comparable. However, the evidence for recommending baclofen for AWS was insufficient.

#### Caveat

There was only 1 small study, with only 37 patients, included in the analysis.

## Context

AWS is a distressing and life-threatening condition affecting some alcohol-dependent patients who discontinue or decrease their alcohol consumption. Baclofen is a stereoselective gamma-aminobutyric acid B (GABAB) receptor agonist with an approved indication to control spasticity.

# Cochrane Systematic Review

Liu J and Wang L. Baclofen for alcohol withdrawal. Cochrane Reviews, 2011, Issue 1. Article No. CD008502. DOI: 10.1002/14658502.CD005216.pub2. This review contains 1 study involving 37 participants.

PEARLS No. 313, June 2011, written by Brian R McAvoy

# Further references

- 1. Fiellin DA et al. Substance Abuse 2002;23:83–94.
- 2. Davidoff RA. Annals of Neurology 1985;17:107-16

PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners – developed by the Cochrane Primary Care Field, New Zealand Branch of the Australasian Cochrane Centre at the Department of General Practice and Primary Health Care, University of Auckland and funded by the New Zealand Guidelines Group. New Zealanders can access the Cochrane Library free via www.nzgg.org.nz

PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online at: www.nzdoctor.co.nz; www.nzgg.org.nz; www.cochraneprimarycare.org



